I agree onestepahead, I am not finding any plausible scenarios that are negative.
They asked us to send in the data as soon as it was unblinded. Sounds like we did. Now we start the analysis.
I'm less clear on the secrecy. Perhaps, as you say they want to get some things in order before they release the data. I suspect its a combination of things. The data is just beginning to be analyzed, but they probably have a general idea of the mortality and p values now.
But until the analysis is done (and perhaps validated by the FDA) they are choosing to stay quiet.